AstraGin®
Astragalus membranaceus and Panax notoginseng root extracts
Astragalus Notoginseng ExtractLast reviewed: July 11, 2026
Medical & Industry Advisor: Dr. James Pendleton, ND
Answer
Availability
We have not verified a current supply status for this ingredient. Unknown is our default: we publish a status only with dated evidence. If you have first-hand sourcing information, use the correction link below.
Owner and access
- Owner
- NuLiv Science (site)
- Access model
- Licensed program
What it is
- Plant-derived blend of Astragalus membranaceus and Panax notoginseng root extracts from NuLiv Science. [nulivscience.com]
Spec parameters buyers should demand
What to ask for on the certificate of analysis and spec sheet. Identity, quality, and regulatory parameters only. This is not advice about efficacy.
| Parameter | What to ask | Why it matters |
|---|---|---|
| Total saponin content (standardization) | NuLiv Science publishes AstraGin standardized to 1.5% total saponins. Request the certificate of analysis stating total saponin content and the method. The EFSA novel-food opinion documents a fuller compositional range (total saponins, plus marker saponins ginsenoside Rb1 and astragaloside I).[nulivscience.com — AstraGin technical data][EFSA Scientific Opinion on AstraGin as a novel food, EFSA Journal 2020;18(5)] | Total saponins is the standardization figure for this combination extract, and the marker saponins are what tie the material to the assessed composition. |
| Dual-botanical identity | Ask the CoA to confirm both root extracts (Astragalus membranaceus and Panax notoginseng) and to document the marker saponins (ginsenoside Rb1, astragaloside I) named in the EFSA compositional spec.[EFSA Scientific Opinion, EFSA Journal 2020;18(5)] | AstraGin is defined by two specific root extracts, so confirming both species and their marker saponins is what identifies the material versus a single-species extract. |
| Identity verification | Confirm the manufacturer runs at least one validated identity test on each incoming lot, as 21 CFR 111.75(a)(1) requires for every dietary ingredient.[21 CFR 111.75(a)(1) — identity test required for each dietary ingredient] | Identity testing is a federal manufacturing requirement, and a certificate that names the method is the record your own quality file needs. |
| Heavy metals | Request lead, arsenic, cadmium, and mercury results with the test method and the limits applied.[21 CFR Part 111 — cGMP for dietary supplements] | Heavy-metal control is a baseline quality attribute for any botanical extract and part of a complete certificate of analysis under 21 CFR Part 111. |
QC and testing considerations
- Every dietary ingredient must pass at least one validated identity test before use (21 CFR 111.75(a)(1)). Confirm your manufacturer runs identity testing on each incoming lot. [21 CFR 111.75(a)(1)]
- AstraGin is a two-species combination; confirm the CoA documents both Astragalus membranaceus and Panax notoginseng and their marker saponins, so a single-species extract is not substituted under the brand name. [EFSA Scientific Opinion, EFSA Journal 2020;18(5)]
- AstraGin has an EFSA novel-food safety opinion; ask for the EFSA reference and any regional authorization on file so the regulatory record travels with the material. [EFSA Scientific Opinion, EFSA Journal 2020;18(5)]
Further reading: How to read a certificate of analysis and third-party supplement testing.
Reference list
- EFSA Scientific Opinion on the safety of a botanical extract from Panax notoginseng and Astragalus membranaceus (AstraGin) as a novel food, EFSA Journal 2020;18(5):6099 Regulatory
- 21 CFR Part 111 — Current Good Manufacturing Practice for dietary supplements (identity testing at 111.75) Regulatory
- AstraGin (NuLiv Science) — Astragalus + Panax notoginseng root extract, owner site Owner technical
A reference list is not claim substantiation. Under the FTC's Health Products Compliance Guidance (December 2022), marketing claims about a finished product require competent and reliable scientific evidence, typically randomized, controlled human clinical testing. Responsibility for substantiating product claims rests with the brand.
Manufacturers with stated capability
No manufacturer has a listed capability for this ingredient yet. Listings are positive-only: an entry states a manufacturer can run the ingredient, never that one cannot.
Run this ingredient? Request inclusion.
Further reading
The decision framework behind this reference: five checkable criteria for choosing between a branded ingredient and its generic form.
What this page does not tell you
- Whether the owner will license your specific product or accept a new account.
- Pricing, minimum order volumes, or contract terms.
- Anything about efficacy. This is an identity and sourcing reference.
Prefills the ingredient into the RFQ Spec Builder. You enter your own formula; the tool formats it into a spec sheet.
AstraGin® is a registered trademark of NuLiv Science. Inventory Ready is not affiliated with, licensed by, or endorsed by the trademark owner.
Represent this ingredient's owner, or see something out of date? Request a correction.
Sourcing this ingredient?
Tell us what you are building. We run the RFQ against assessed manufacturers and report back what we find, including current availability.